U of Oklahoma taps ABT for FDG production
The University of Oklahoma in Norman, Okla., has completed installing ABT Molecular Imaging's Biomarker Generator at the College of Pharmacy, enabling researchers at the university to have local access to PET radioisotopes.
The system combines a radioisotope generator with “kit-based” micro-chemistry, providing single-dose production of PET biomarkers used for molecular imaging. “Space and budget were a real concern for us when it came to integrating PET radiopharmaceutical production into our drug development programs,” said Vibhu Awasthi, MD, associate professor in the department of pharmaceutical sciences at the University of Oklahoma and current president of the Indo-American Society of Nuclear Medicine.
The system is installed in an 18-by-18-foot room located near the preclinical PET scanner, where imaging services are provided to researchers within the Oklahoma Health Sciences Center corridor.
The Biomarker Generator produces the PET biomarker, FDG, for today’s clinical needs and is adaptable for future positron-emitting radionuclides and PET biomarkers, according to the Knoxville, Tenn.-based company. The system provides single FDG dose production every 30 minutes, and will provide F-18 and C-11 biomarkers for research in the near future.
The system combines a radioisotope generator with “kit-based” micro-chemistry, providing single-dose production of PET biomarkers used for molecular imaging. “Space and budget were a real concern for us when it came to integrating PET radiopharmaceutical production into our drug development programs,” said Vibhu Awasthi, MD, associate professor in the department of pharmaceutical sciences at the University of Oklahoma and current president of the Indo-American Society of Nuclear Medicine.
The system is installed in an 18-by-18-foot room located near the preclinical PET scanner, where imaging services are provided to researchers within the Oklahoma Health Sciences Center corridor.
The Biomarker Generator produces the PET biomarker, FDG, for today’s clinical needs and is adaptable for future positron-emitting radionuclides and PET biomarkers, according to the Knoxville, Tenn.-based company. The system provides single FDG dose production every 30 minutes, and will provide F-18 and C-11 biomarkers for research in the near future.